Dr. David B. Van Holla, a distinguished psychiatrist with over two decades of experience, is revolutionizing mental health care through groundbreaking advancements in blood-based gene expression diagnostics and therapeutic monitoring. Dr. Van Holla's expertise spans general outpatient psychiatry, where he provides comprehensive psychiatric evaluation, diagnosis, treatment, and medication management for patients grappling with mental, emotional, and behavioral disorders.

Dr. Van Holla is at the forefront of the mental/behavioral health field, spearheading genomic discovery through his corporation, Superior Genomics. His pioneering work focuses on harnessing the power of gene expression blood tests to enhance diagnostics and therapeutic monitoring in the realm of mental health.

With a career spanning over 20 years, Dr. Van Holla has become a luminary in general outpatient psychiatry. He is deeply committed to educating the next generation of medical professionals, actively engaged in teaching students and resident physicians in the field of psychiatry. His tireless efforts have been instrumental in advancing the field of mental health by pioneering diagnostics and therapeutic monitoring through gene expression blood tests.

Dr. Van Holla's educational journey is rooted in a strong foundation. He earned his MD from Michigan State University College of Human Medicine in 1999, followed by a residency in psychiatry at Michigan State University from 2000 to 2003. His extensive training also includes a family practice residency from 1999-2000. Dr. Van Holla's dedication to excellence in psychiatry is further underscored by his board certification in psychiatry and Diplomate status with the American Board of Psychiatry and Neurology (ABPN). He is also recognized as a Fellow of the American Psychiatric Association (FAPA).

As a Fellow of the American Psychiatric Association and Diplomate of the ABPN, Dr. Van Holla has amassed numerous career accomplishments. His distinguished career has encompassed over two decades of clinical care in both employed and self-employed settings. He has maintained an active role in academia, teaching medical students and resident physicians. Moreover, Dr. Van Holla's collaborative efforts have led to groundbreaking discoveries in blood-based gene expression bioprofiles for mental health diagnostics and therapeutic monitoring. Under his interim leadership, the biotech startup Superior Genomics is poised to commercialize these pioneering genomic discoveries.

One of the most notable achievements in Dr. Van Holla's career is the development of an objective blood test that can differentiate between the depressive symptoms of Major Depressive Disorder and Bipolar Disorder, a significant milestone in mental health diagnostics.

Dr. Van Holla's career journey has seen him practice as a general psychiatrist in Michigan's Upper Peninsula for over two decades. He has managed a private solo practice in Norway, Michigan, and served as an attending psychiatrist at the Oscar G. Johnson VA Medical Center. Additionally, his experience extends to the pharmaceutical industry, where he has served as a speaker for major pharmaceutical companies. Collaborating with Paradise Genomics, he has played a pivotal role in overseeing the development of mental health diagnostics and therapeutic monitoring assays utilizing gene expression.

Dr. Van Holla attributes his success to the guidance and mentorship of esteemed figures in the field of psychiatry, including Dr. Lynn Miller MD, Dr. Tony Holzgang MD, Dr. Lonnie Rosen MD, and Dr. Arnie Werner MD. More recently, Dr. Scott Magnuson PhD and Dr. Michael Falduto PhD have encouraged his career trajectory in genomics.

Dr. Van Holla expresses heartfelt gratitude to his family for their unwavering love and support throughout his journey.

Looking ahead, Dr. Van Holla's future projections center on his passionate pursuit of advancing the field of mental health by making objective blood tests readily available to clarify diagnoses and therapeutically monitor patients grappling with mental illness. These precise blood tests hold the potential to empower clinicians in both mental health and non-psychiatric fields, enabling them to initiate timely and appropriate treatments with greater confidence.

At the heart of Dr. Van Holla's philosophy lies a commitment to individualized patient care. He emphasizes the importance of remaining patient-centered in clinical practice, even in the face of external pressures. In the realm of mental health, he believes it is crucial for clinicians to consider both physiology and behavior when working towards helping patients on their path to recovery.